Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07453433 | Submucosal Pressure Ejection Endoscopic Dissection for Early Gastric Cancer: a Retrospective Cohort Study | completed | — | 548 | Shanghai East HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 |
| NCT05432492 | A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449065 | CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC | completed | — | 324 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02110498 | Early Detection of Pancreatic Cystic Neoplasms | completed | — | 3,000 | Johns Hopkins UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02184416 | Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting(ADONIS) | completed | — | 554 | PfizerINDUSTRY | 8 | Feb 27, 2026 | clinicaltrials |
| NCT07436416 | Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer(EXO-RENAL2) | completed | N/A | 91 | Institute of Oncology LjubljanaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04945720 | Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment(PASS-01) | completed | Phase 2 | 150 | University Health Network, TorontoOTHER | 2 | Feb 20, 2026 | clinicaltrials |
| NCT06160466 | Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in Follow-up Patients in a Screening Setting(GENIAL-CO FU) | completed | N/A | 1,156 | Fondazione Poliambulanza Istituto OspedalieroOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07407257 | SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors | completed | N/A | 65 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416409 | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | completed | — | 80 | Deraya UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07418138 | Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation | completed | — | 484 | Hu LiangshuoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02530489 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03463876 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | completed | Phase 2 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04418401 | Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients(CISLD-8) | completed | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03301350 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | completed | Phase 2 | 29 | University of Wisconsin, MadisonOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07404566 | Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients | completed | — | 84 | Benha UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07406646 | Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)(EXO-RENAL1) | completed | N/A | 91 | Institute of Oncology LjubljanaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT07398820 | IMPACT OF SEDENTARY BEHAVIOR IN THE HOMEOSTASIS OF THE DIGESTIVE ECOSYSTEM | completed | — | 80 | Clínica Universidad de los AndesOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07391514 | Deep Learning-Based Intraoperative Dual-tracer Video Analysis of Sentinel Lymph Node Mapping for Metastasis Prediction in cN0 Papillary Thyroid Carcinoma | completed | — | 131 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT06235814 | Molecular Analysis for Precision Surgery in Thyroid Cancer Trial(MAPS) | completed | N/A | 2 | University of California, Los AngelesOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT07386639 | Sex-Specific Machine Learning Models to Predict Distant Metastasis in Liver Cancer(GENDER-HCC-MET) | completed | — | 19,019 | Tongji UniversityOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06310590 | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 40 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | completed | Phase 1 | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | completed | Phase 1 | 39 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06631326 | HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) | completed | — | 244 | First Hospital of China Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06335108 | Postoperative Pain After Breast Surgery Under Tumescent Local Anaesthesia Versus General Anaesthesia ( TLA-001 ) | completed | — | 349 | University Hospital TuebingenOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07368530 | Using Machine Learning to Identify Responders to TACE or HAIC for uHCC | completed | — | 3,000 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT00625755 | A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04524702 | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | completed | Phase 2 | 10 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05166239 | HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | completed | Phase 2 | 66 | Peking UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02158507 | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | completed | N/A | 20 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2026source: clinicaltrials